3E0.F ESTABLISHMENT LABS HLDGS
- Market cap
- EUR 1.79B
- P/E
- -
- P/B
- 128.86x
- ROE
- -306.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 3E0.F undervalued?
Graham numberThe Graham number of ESTABLISHMENT LABS HLDGS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ESTABLISHMENT LABS HLDGS fundamental analysis
No fundamental analysis for ESTABLISHMENT LABS HLDGS yet.
ESTABLISHMENT LABS HLDGS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ESTABLISHMENT LABS HLDGS
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales…
Full company profileESTABLISHMENT LABS HLDGS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ESTABLISHMENT LABS HLDGS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 127M | 162M | 165M | 166M | 211M | 266M |
| Gross Profit | 85.4M | 107M | 107M | 110M | 146M | 186M |
| Operating Income | -25.1M | -39.7M | -65.0M | -50.0M | -39.0M | -17.9M |
| EBITDA | - | -56.7M | -58.3M | -56.2M | -22.3M | -7.96M |
| Net Income | -41.1M | -75.2M | -78.5M | -84.6M | -51.1M | -47.8M |
| EPS | -1.71 | -3.08 | -3.01 | -2.94 | -1.74 | -1.60 |
| Balance Sheet | ||||||
| Total Assets | 140M | 211M | 269M | 347M | 357M | 359M |
| Total Liabilities | 88.8M | 219M | 250M | 294M | 334M | 343M |
| Shareholders' Equity | 50.7M | -8.19M | 18.4M | 53.1M | 23.5M | 15.6M |
| Cash & Short-term Investments | 53.4M | 66.4M | 40.0M | 90.3M | 75.6M | 75.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -27.5M | -52.2M | -88.5M | -58.5M | -50.9M | -17.6M |
| Capital Expenditure | 6.73M | 34.3M | 24.5M | 15.6M | 6.72M | 11.0M |
| Free Cash Flow | -34.3M | -86.4M | -113M | -74.1M | -57.6M | -28.6M |
| Ratios | ||||||
| ROE | -81.1% | - | -426.8% | -159.3% | -216.9% | -306.4% |
| ROA | -29.5% | -35.6% | -29.2% | -24.4% | -14.3% | -13.3% |
| Net Profit Margin | -32.5% | -46.5% | -47.5% | -51.0% | -24.2% | -18.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ESTABLISHMENT LABS HLDGS dividends
ESTABLISHMENT LABS HLDGS has not paid dividends in the last 5 fiscal years.
Who owns ESTABLISHMENT LABS HLDGS
- Insiders 10.03%
- Institutions 89.97%
- Public & others 0.00%
- Shares outstanding 29.8M
- Free float 19.8M
ESTABLISHMENT LABS HLDGS company profile
- Company name
- ESTABLISHMENT LABS HLDGS
- Ticker
- 3E0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,004
- Fiscal year end
- December
- Address
- 11401 century oaks terrace, Austin, TX, United States, 78758
- Phone
- 800 924 5072
- Website
- establishmentlabs.com
About ESTABLISHMENT LABS HLDGS
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
ESTABLISHMENT LABS HLDGS management
4- Mr. Fillipo Peter CaldiniCEO & Director · born 1965
- Ms. Cassandra E. HarrisSenior VP & CFO · born 1973
- Mr. Roberto de MezervilleChief Technology Officer · born 1980
- Ms. Malavika WilliamVP, Global Head of Marketing & Communications